ARTICLE | Company News

Bavarian Nordic deal

November 23, 2009 8:00 AM UTC

Bavarian Nordic will acquire the remaining 85% its R&D subsidiary BN ImmunoTherapeutics Inc. (Palo Alto, Calif.) it does not already own in a stock deal. BN ImmunoTherapeutics CEO Reiner Laus and two employees will receive up to DKK52 million ($10.5 million) in stock and potential milestones. Laus also is eligible for an additional DKK26 million ($5.2 million) in milestones. ...